Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.55 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511410 | 0.99 | DPP4 (0.61) | DPP4TDP1NPC1CASP3RAB9A | |
| Hydrochloric Acid SCHEMBL1820938 | 0.99 | DPP4 (0.61) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL5991627 | 0.99 | DPP4 (0.61) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL3509404 | 0.88 | DPP4 (0.58) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL3511025 | 0.88 | DPP4 (0.58) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL27462751 | 0.86 | DPP4 (0.62) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL4810741 | 0.86 | S1PR1 (0.65) | S1PR1S1PR4S1PR3S1PR5S1PR2 | |
| SCHEMBL4818458 | 0.85 | S1PR1 (0.67) | S1PR1S1PR4S1PR3S1PR5S1PR2 | |
| SCHEMBL27529280 | 0.85 | DPP4 (0.61) | DPP4TDP1NPC1CASP3RAB9A | |
| SCHEMBL27553090 | 0.85 | DPP4 (0.61) | DPP4TDP1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117065037-A | Pharmaceutical compositions comprising S1P modulators | 诺华股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-110548011-A | Pharmaceutical compositions comprising S1P modulators | NOVARTIS AG | 2019-12-10 | — | — | CN | claimed |
| EP-3103448-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN S1P MODULATOR | NOVARTIS AG (CH) | 2016-12-14 | — | — | EP | claimed |
| EP-1915130-B1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | claimed |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | claimed |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | claimed |
| US-20140227358-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | claimed |
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | claimed |
| US-20120288559-A1 | ORGANIC COMPOUNDS | AMBUEHL MICHAEL (US) | 2012-11-15 | — | — | US | claimed |
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | FOSTER CAROLYN ANN (AT) | 2012-09-06 | — | — | US | claimed |
| US-20060275357-A1 | Organic compounds | OOMURA TOMOYUKI | 2006-12-07 | — | — | US | claimed |
| US-RE39072-E1 | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-18 | — | — | US | claimed |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | FOSTER CAROLYN A | 2006-03-02 | — | — | US | claimed |
| EP-1613288-A1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL | Novartis AG (CH) | 2006-01-11 | — | — | EP | claimed |
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | claimed |
| WO-2004089341-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | claimed |
| EP-1002792-B1 | 2-AMINOPROPANE-1,3-DIOL COMPOUNDS, MEDICINAL USE THEREOF, AND INTERMEDIATES IN SYNTHESIZING THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-07-14 | — | — | EP | claimed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | claimed |
| US-6214873-B1 | PREVENTION OR SUPPRESION OF REJECTION OF ORGANS OR BONE MARROW TRANSPLANTATION; TREATMENT OF AUTOIMMUNE DISEASES OR ALLERGIC DISEASES; DECREASE IN TOXICITY AND HIGHER SAFETY | WELFIDE CORPORATION (JP) | 2001-04-10 | — | — | US | claimed |
| EP-1002792-A1 | 2-AMINOPROPANE-1,3-DIOL COMPOUNDS, MEDICINAL USE THEREOF, AND INTERMEDIATES IN SYNTHESIZING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-05-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | DPP4 1685/4885TDP1 393/4885NPC1 1432/4885 |
| US-20060275357-A1 | Organic compounds | S1PR1, S1PR2, S1PR3 | DPP4 1531/4885TDP1 3572/4885NPC1 167/4885 |
| US-20140227358-A1 | ORGANIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | DPP4 1686/4885TDP1 2821/4885NPC1 405/4885 |
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | S1PR5, S1PR2, S1PR1 | DPP4 2230/4885TDP1 3115/4885NPC1 675/4885 |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | S1PR1, S1PR4, S1PR2 | DPP4 1298/4885TDP1 165/4885NPC1 834/4885 |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | DPP4 1685/4885TDP1 393/4885NPC1 1432/4885 |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | S1PR1, S1PR2, S1PR4 | DPP4 3457/4885TDP1 2062/4885NPC1 408/4885 |
| US-20120288559-A1 | ORGANIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | DPP4 1686/4885TDP1 2821/4885NPC1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.